Jazz Pharmaceuticals (J7Z) Stock Statistics & Valuation Metrics

Jazz Pharmaceuticals has a market cap or net worth of CHF12.28B. The enterprise value is $17.83B.

Jazz Pharmaceuticals has ― shares outstanding. The number of shares has decreased by -2.65% in one year.

Jazz Pharmaceuticals’s return on equity (ROE) is -0.08 and return on invested capital (ROIC) is 1.22%.

The current PE Ratio of Jazz Pharmaceuticals is 593.8. Jazz Pharmaceuticals’s PEG ratio is 0.18.

In the last 12 months, Jazz Pharmaceuticals had revenue of 4.27B and earned -356.15M in profits. Earnings per share was -5.84.

In the last 12 months, operating cash flow was 1.33B and capital expenditures -88.57M, giving a free cash flow of 1.25B billion.

Jazz Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Jazz Pharmaceuticals upcoming earnings date is Aug 5, 2026, After Close (Confirmed).

Jazz Pharmaceuticals as a current ratio of 1.86, with Debt / Equity ratio of 119.52%

In the past 12 months, Jazz Pharmaceuticals has paid -272.44M in taxes.

Jazz Pharmaceuticals EV to EBITDA ratio is 132.76, with an EV/FCF ratio of 12.56.

Jazz Pharmaceuticals has CHF2.87B in cash and marketable securities with CHF5.42B in debt, giving a net cash position of -CHF2.54B billion.

Gross margin is 84.12%, with operating margin of 5.26%, and net profit margin of -8.35%.

The average price target for Jazz Pharmaceuticals is CHF212.78, which is 11.43% higher than the current price. The consensus rating is Strong Buy